HomeNews › Abrasion-Resistant and Award-Winning: TEVA Relies on Schreiner MediPharm for Novel Adrenaline Injector Label
08-06-20
Member news

Abrasion-Resistant and Award-Winning: TEVA Relies on Schreiner MediPharm for Novel Adrenaline Injector Label

Patients suffering from life-threatening allergies always carry a life-saving companion with them: an adrenaline autoinjector in order to immediately inject themselves in the event of an anaphylactic shock and to thus counter an allergic reaction. For the emergency drug epinephrine from TEVA, Schreiner MediPharm developed an Autoinjector-Label with special protection against abrasion. Thus, the vital user and product information remains perfectly legible over an extended period of time. The label won an award in the 2019 TLMI Competition.

Epinephrine is a prescription drug for the treatment of life-threatening allergic emergencies. TEVA, a worldwide leader in generic drugs and specialty medicines, offers the adrenaline in single-dose, prefilled disposable autoinjectors. The label developed by Schreiner MediPharm for this injector is provided with abrasion- and scratch-resistant reverse printing. As a result, it is particularly resistant against chemical and mechanical impacts it is exposed to while the autoinjector is being carried in a purse or backpack, for instance. Due to its special material construction and design that is precisely adapted to the sophisticated shape of the autoinjector, the marking label securely adheres to the device. Thus, the vital information about the product and its use is reliably legible and readily available at all times. An additional cover protecting the label against abrasion or separation is not necessary, which reduces waste and the environmental footprint. For product and patient safety, the label features a perforation that clearly and irreversibly indicates any first opening of the cap and thus any potential tampering attempt.

The TEVA Autoinjector-Label won recognition in the yearly North American Tag and Label Manufacturers Institute (TLMI) Competition that awarded Schreiner MediPharm’s product development with second place in the “Multi-Process” category in 2019.